Tag Archives: China

California Life Sciences to Partner with China

By Ben Comer | Published: April 13, 2011
BIOCOM, a trade group representing Southern California’s life sciences industry, is ramping up partnership efforts in China to meet an emerging desire for novel drug therapies. While intellectual property (IP) protections and the Chinese government’s willingness to pay for expensive new products represent two large and lingering question marks, Joe Panetta, president and CEO at BIOCOM, [...]
Posted in Biotech, Emerging Markets, Global, IP, Market Access, R&D, leadership | Also tagged , , , | Leave a comment

New Decade, New Agenda for Pharma

By Guest Blogger | Published: January 12, 2011
A new track for nonprofits, product diversification and the rise of the emerging markets —  Audrey S. Erbes reports on some of the takeaways from this week’s JP Morgan Healthcare Conference. There were some surprising changes in the format of the 29th Annual JP Morgan Healthcare Conference, the world’s premier health care industry investment meeting which [...]
Posted in Emerging Markets, Guest Blog, R&D | Also tagged , , , , | Leave a comment

Fixing Biotech's Broken Business Model

By Julian Upton | Published: December 22, 2010
Despite some notable successes, the global biotech industry has fallen short of expectations. Strategic collaborations have been on the increase, but there is now a need for more co-operation using new collaboration models, writes Jo Pisani. The current business model on which biotech has relied is flawed. Due to poor rates of return, investment has dried [...]
Posted in Biotech, Deals, Emerging Markets, Europe, Global, Guest Blog, R&D | Also tagged , , , , , , , | Leave a comment

Drug Payment Reform in China: Now That's a Mass Market

By William Looney | Published: November 10, 2010
The task of building drug access for one billion new customers in China is probably this decade’s grandest public policy experiment.  It is taking place largely behind the scene in a series of often tense exchanges between Beijing and local governments – the dialogue is worth watching for the long-term commercial implications in what all [...]
Posted in Emerging Markets, Global, Strategy | Also tagged , , | Leave a comment

US and Europe At Risk from Substandard Medicines

By Julian Upton | Published: February 25, 2010
Guest blog by Helen Disney, Chief Executive and Founder of the Stockholm Network, a pan-European think tank. When most of us look at taking a new medicine we tend to think it will make us better. Some of us may think about possible side effects but few of us expect the medicines we take to actually [...]
Posted in Biotech, Emerging Markets, Europe, Global, Guest Blog, Regulatory, Safety | Also tagged , , , , , , , , , , | Leave a comment